TAKE STEPS TO AVOID LEADING CAUSE OF BLINDNESS People of African descent at higher risk of Glaucoma Seek Glaucoma screening this World Glaucoma Week, urges Novartis Thousands of South Africans are unaware that they have Glaucoma, a leading cause of blindness. Ahead of World Glaucoma Week from March 10-16, Novartis South Africa urges South Africans to be aware of their risk and to take steps to have the disease diagnosed as early as possible. Sometimes called the ‘silent thief in the night’ because patients may lose their peripheral vision slowly with no symptoms1, Glaucoma is a group of disorders that leads to damage of the optic nerve. Glaucoma is often associated with increased eye pressure, although it may also occur with normal eye pressure. This slowly progressive disease leads to irreversible loss of vision and can result in blindness if not diagnosed and treated early2. Glaucoma specialist and Ophthalmologist at the Chris Hani Baragwanath St John Eye Hospital, Dr Philip Phatudi, says too few people are aware of the risks of Glaucoma. “We see patients daily who come in with another complaint, and we discover they have undiagnosed and advanced Glaucoma,” says Dr Phatudi. “Clearly the message isn’t filtering out that people need to be aware of the risks, and have regular Glaucoma tests if they are in a higher risk group. The nasty thing about Glaucoma is – once you realise your vision has deteriorated, it is already too late and the damage already caused is permanent.” Dr Phatudi advises any adults with a family history of Glaucoma, people who are short-sighted, and anyone over the age of 40 to have regular screenings for Glaucoma. People over the age of 40 have a higher risk of developing Glaucoma, and people of African descent have a higher Glaucoma risk than those of European descent. Glaucoma is a leading cause of blindness worldwide, with up to 70 million people suffering from it1 and an estimated 10% going blind as a result2. In South Africa, an estimated 200,000 people have Glaucoma2. Glaucoma can present at any age, although the commonest type – Primary Open Angle Glaucoma – usually occurs after the age of 402. In South Africa, the prevalence of Glaucoma in people older than 40 is between 4.5% and 5.3%. In whites, 1 in 40 people over the age of 40 years will develop glaucoma (2%). The prevalence in African-Americans and African-Caribbeans over 40 years of age is 4 times higher1. If left untreated, most types of glaucoma progress without warning or obvious symptoms to the patient towards gradually worsening vision, and may lead to blindness. Glaucoma is the second most common cause of blindness worldwide, but despite its prevalence, it is estimated that up to 50% of affected people in the developed countries and as many as 90% of people in under-developed parts of the world, are not even aware they have Glaucoma3. The most common types of adult-onset Glaucoma are Primary Open Angle Glaucoma (POAG) – a form most frequently encountered in patients of Caucasian and African ancestry – and Angle-Closure Glaucoma (ACG), which is the more common in patients of Asian ancestry. Angle-Closure Glaucoma is often chronic, like POAG, but can sometimes be acute, in which case it usually presents as a very painful ocular condition leading to rapid vision loss3. There is no cure for Glaucoma yet, but medication or surgery (traditional or laser) can halt or slow down any further vision loss3. “We have technology that is able to detect early features of glaucoma, so we are now able to start treatment at an early stage and slow the progression of the disease. The earlier we detect Glaucoma, the better,” says Dr Phatudi. Aiming to help raise awareness of the risks of Glaucoma, Novartis South Africa will participate in World Glaucoma Week 2019 by supporting health professionals with disease and treatment information for patients. Dr Chris Nathaniel, Medical Head – Specialty Care: Southern Africa at Novartis SA says: “With so many people undiagnosed, we want to help raise awareness of the risks, and inform people that treatment is available to slow down the progression of the disease. We will be supporting clinics and hospitals in a number of provinces by distributing patient information packs,” says Dr Nathaniel. Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis For Novartis multimedia content, please visit www.novartis.com/news/media-library For questions about the site or required registration, please contact firstname.lastname@example.org References Glaucoma: The least the general practitioner should know. A A Stulting,1 MB ChB, MMed (Ophth), FCS(SA) (Ophth), FRCOphth (UK), FEACO (Hon), FCMSA (Hon), FACS, FICS; M Labuschagne,2 MB ChB, MMed (Ophth), PhD (HPE) http://www.cmej.org.za/index.php/cmej/article/view/2711/2906. Accessed 21/02/2019 South African Glaucoma Society Patient Information https://www.sags.co.za/. Accessed 21/02/2019 World Glaucoma Week: What is Glaucoma https://www.worldglaucomaweek.org/what-is-glaucoma/ Accessed 21/02/2019 Leave a Reply Cancel ReplyYou must be logged in to post a comment.